News & Analysis as of

Biden Administration Proposed Legislation Health Care Providers

Brownstein Hyatt Farber Schreck

Biden Reveals Health Care Priorities in FY 2025 Budget

On Monday, March 11, President Joe Biden unveiled his fiscal year (FY) 2025 budget request, the fourth of his presidency. The $7.3 trillion proposal calls for approximately $1.9 trillion in discretionary spending, $4.4...more

WilmerHale

State Governments Move to Regulate AI in 2024

WilmerHale on

Recently, New York Governor Kathy Hochul proposed sweeping artificial intelligence (AI) regulatory measures intended to protect against untrustworthy and fraudulent uses of AI. Presented as part of her FY 2025 Executive...more

Holland & Knight LLP

Holland & Knight Health Dose: February 6, 2024

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector....more

McDermott+

Healthcare Preview for the Week of: June 5, 2023

McDermott+ on

Debt Limit Extended . . . Now What? Late last week, Congress reached a bipartisan, bicameral deal to suspend the debt ceiling into 2025. Over the weekend, President Biden signed the bill into law, preventing the United...more

Holland & Knight LLP

Holland & Knight Health Dose: May 23, 2023

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector. This week's topics include ... ...more

Holland & Knight LLP

Holland & Knight Health Dose: April 18, 2023

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector. This week's topics include... ...more

Latham & Watkins LLP

Health Care & Life Sciences: Drug Pricing Digest - December 2022

Latham & Watkins LLP on

Inflation Reduction Act Implementation: On Dec. 1, 2022, the Centers for Medicare & Medicaid Services (CMS) distributed an invitation addressed to “All Drug Manufacturers” announcing that CMS “will host monthly one-hour calls...more

Holland & Knight LLP

Holland & Knight Health Dose: August 9, 2022

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector. This week's topics include . . . ...more

Brownstein Hyatt Farber Schreck

Government Focus on Medical Debt and Credit Reporting Could Impact Various Industries

White House Activity Surrounding Medical Debt   - On April 11, 2022, the White House announced plans in line with a recent government focus on medical debt and credit reporting that could impact medical providers, the...more

Brownstein Hyatt Farber Schreck

Summary of Policies in the Fiscal Year 2023 Health and Human Services Budget Request

Last week, President Biden released the administration’s Fiscal Year (FY) 2023 Budget proposal. The Budget presents an ideological vision the administration would like to see Congress adopt. Along with a holistic document...more

Holland & Knight LLP

2022 Congressional Outlook and Top 10 Federal Health Policy Issues to Watch

Holland & Knight LLP on

As Congress reconvenes, it faces a packed agenda in a legislative year that will be shortened by the upcoming midterm elections and remains buffeted by the persistent coronavirus pandemic. The list of healthcare priorities is...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - January 2022

Latham & Watkins LLP on

Drug Pricing Initiatives: The pathway to Senate passage of H.R. 5376 (the Build Back Better Act, or BBBA) is unclear, following Senator Joe Manchin’s withdrawal of his support for the measure. The BBBA is an approximately...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - December 2021 #2

Latham & Watkins LLP on

Drug Pricing Initiatives: President Biden has indicated that a Senate vote on H.R. 5376 (the Build Back Better Act, or BBBA) will likely not occur until 2022. This follows conversations between President Biden and Senator Joe...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - November 2021 #2

Latham & Watkins LLP on

Drug Pricing Initiatives: On Nov. 19, 2021, the House of Representatives passed H.R. 5376 (the Build Back Better Act, or BBBA), the approximately $2.2 trillion social safety net, climate, and tax bill that includes measures...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - October 2021

Latham & Watkins LLP on

Drug Pricing Initiatives: The fate of the reconciliation package that contains many of President Biden’s domestic policy initiatives, including with respect to drug pricing, remains in limbo as Democrats continue to debate...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - August 2021 #3

Latham & Watkins LLP on

Drug Pricing Initiatives: On Aug. 24, 2021, the House of Representatives approved a $3.5 trillion budget framework, S. Cons. Res. 14, while also voting to advance the $1 trillion infrastructure bill. The deadline for the...more

Latham & Watkins LLP

Healthcare & Life Sciences: Drug Pricing Digest - August 2021 #2

Latham & Watkins LLP on

$1 Trillion Infrastructure Bill Includes Two Drug Pricing Provisions: On Aug. 10, 2021, the Senate passed H.R. 3684, the Investing in a New Vision for the Environment and Surface Transportation in America Act, or the INVEST...more

17 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide